

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

Kelly

RRID:CVCL_2092

Type: Cell Line

Proper Citation

RRID:CVCL_2092

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2092

Proper Citation: RRID:CVCL_2092

Description: Cell line Kelly is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Neuroblastoma

Defining Citation: [PMID:2846152](#), [PMID:6888561](#), [PMID:7139592](#), [PMID:10630978](#), [PMID:11668190](#), [PMID:17506115](#), [PMID:18082704](#), [PMID:18724359](#), [PMID:18923524](#), [PMID:22460905](#), [PMID:24466371](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28350380](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:33525507](#), [PMID:35839778](#), [PMID:39255063](#)

Comments: Virology: Infected with a murine leukemia virus-related virus (PubMed=30629668)., Characteristics: MYCN-amplified NBL cell line., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Kelly

Synonyms: KELLY, NB19, NB-19, NB19-RIKEN

Cross References: BTO:BTO_0006213, CLO:CLO_0007091, CLO:CLO_0051540, EFO:EFO_0002069, CLDB:cl3020, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:623, BioSample:SAMN03472324, BioSample:SAMN03473084,

BioSample:SAMN03473316, BioSample:SAMN10988299, cancercellines:CVCL_2092, Cell_Model_Passport:SIDM01009, ChEMBL-Cells:CHEMBL4651376, CLS:300317, Cosmic:688077, Cosmic:753618, Cosmic:801738, Cosmic:920246, Cosmic:947704, Cosmic:1037341, Cosmic:1099138, Cosmic:1109365, Cosmic:1153786, Cosmic:1161990, Cosmic:1167409, Cosmic:1167987, Cosmic:1212537, Cosmic:1995468, Cosmic:2058107, Cosmic:2131576, Cosmic:2393634, Cosmic:2485945, Cosmic-CLP:753618, DepMap:ACH-000259, DSMZ:ACC-355, DSMZCellDive:ACC-355, ECACC:92110411, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:753618, GEO:GSM313805, GEO:GSM313806, GEO:GSM333801, GEO:GSM563354, GEO:GSM887206, GEO:GSM888279, GEO:GSM1366407, GEO:GSM1669983, GEO:GSM2371238, GEO:GSM2394386, GEO:GSM3145616, GEO:GSM3145714, GEO:GSM4104577, GEO:GSM4104578, GEO:GSM4104626, GEO:GSM4104627, GEO:GSM4105308, GEO:GSM4105309, GEO:GSM4105310, GEO:GSM4105311, GEO:GSM4105312, IARC_TP53:28354, LiGeA:CCLE_776, LINCS_LDP:LCL-1966, Lonza:1024, PharmacDB:KELLY_743_2019, PRIDE:PXD003596, PRIDE:PXD030304, Progenetix:CVCL_2092, Progenetix:CVCL_B322, PubChem_Cell_line:CVCL_2092, RCB:RCB0479, Wikidata:Q54899802

ID: CVCL_2092

Record Creation Time: 20220427T220701+0000

Record Last Update: 20260829T234411+0000

Ratings and Alerts

No rating or validation information has been found for Kelly.

Warning: Discontinued: RCB; RCB0479

Virology: Infected with a murine leukemia virus-related virus (PubMed=30629668)., Characteristics: MYCN-amplified NBL cell line., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 49 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lou E, et al. (2026) Super-enhancer-driven TCF4 orchestrates neuroblastoma metastasis by sphingolipid-dependent membrane remodeling and ITGB1-FAK activation. Neuro-oncology, 28(5), 1335.

Pommerenke C, et al. (2026) Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. *iScience*, 29(7), 116469.

Guyot C, et al. (2026) IL4i1 activity generates oncometabolites that rescue neuroblastoma cells from oxidative death. *Cell reports*, 45(6), 117441.

Ludwig M, et al. (2026) YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. *Cancers*, 18(3).

Lindsay J, et al. (2026) Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma. *Molecular cancer therapeutics*, 25(4), 635.

Burke CM, et al. (2026) Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. *Molecular cancer therapeutics*, 25(1), 156.

Jungwirth J, et al. (2026) The Host Cell Factor Phosphatase-2A Subunit PR130 Restricts Replication of Herpes Simplex Virus Type-1. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e23697.

Karapouliou C, et al. (2025) HMMR has oncoprotein-like properties in neuroblastoma cells and high HMMR expression has independent prognostic potential in neuroblastomas. *Scientific reports*, 15(1), 40434.

Tiburcio PDB, et al. (2025) PD-L1 Expression is Mediated by microRNA Processing, Wnt/ β -Catenin Signaling, and Chemotherapy in Wilms Tumor. *Pediatric blood & cancer*, 72(9), e31852.

Hollander JF, et al. (2025) Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. *Cancer research communications*, 5(1), 167.

Treis D, et al. (2025) Targeted inhibition of WIP1 and histone H3K27 demethylase activity synergistically suppresses neuroblastoma growth. *Cell death & disease*, 16(1), 318.

Za?uska-Ogryzek K, et al. (2025) Isobolographic interactions of cannabidiol and AM 1172 with cisplatin in human neuroblastoma and glioblastoma cell lines: An in vitro study. *Chemico-biological interactions*, 408, 111392.

Azfar M, et al. (2025) The polyamine transporter ATP13A3 mediates difluoromethylornithine-induced polyamine uptake in neuroblastoma. *Molecular oncology*, 19(3), 913.

Murra N, et al. (2025) Regulation and Function of CCL2 and N-Myc in Retinoic Acid-treated Neuroblastoma Cells. *Cancer genomics & proteomics*, 22(1), 90.

Kailayangiri S, et al. (2024) Protocol for assessing GD2 on formalin-fixed paraffin-embedded tissue sections using immunofluorescence staining. *STAR protocols*, 5(3), 103199.

Stöber MC, et al. (2024) Intercellular extrachromosomal DNA copy-number heterogeneity drives neuroblastoma cell state diversity. *Cell reports*, 43(9), 114711.

Abu-Zaid A, et al. (2024) Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma. *Cell reports. Medicine*, 5(3), 101468.

Jablonowski CM, et al. (2024) Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to splicing inhibitor. *eLife*, 12.

Scardovi AL, et al. (2024) Preclinical Pharmacokinetics in Tumors and Normal Tissues of the Antigene PNA Oligonucleotide MYCN-Inhibitor BGA002. *Nucleic acid therapeutics*, 34(4), 173.

Volegova MP, et al. (2024) The MYCN 5' UTR as a therapeutic target in neuroblastoma. *Cell reports*, 43(5), 114134.